
Amgen Announces 60% Reduction in List Price of PCSK9 Inhibitor Evolocumab
Amgen has announced that the price of its proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, evolocumab (Repatha), will be reduced by 60%, from an annual price of $14,100 down to $5850.
In alignment with the American Heart Association’s Value in Healthcare Initiative, Amgen has announced that the price of its proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, evolocumab (Repatha), will be reduced by 60%, from an annual price of $14,100 down to $5850.
Evolocumab was
However, the launch price of these drugs was a point of contention and debate for a while. Alirocumab also had an annual price tag of over $14,000.
An early report from the Institute for Clinical and Economic Review (ICER) proposed that the PCSK9 inhibitors
Earlier this year, Sanofi and Regeneron
In a press release, Amgen’s chairman and CEO, Robert A. Bradway pointed out that patient out-of-pocket cost burden is a big barrier to access for the significant number of patients who suffer from cardiovascular disease—including 75% of Medicare patients who are prescribed a PCSK9 inhibitor but never fill the prescription because of the price burden. “We want to make sure that every patient who needs Repatha gets Repatha,” Bradway said.
Amgen has been offering payers significant rebates on Repatha in exchange for improved patient access through tactics such as healthcare utilization management criteria. Additionally, agreements with payers representing greater than 65% of Repatha's commercial revenue are currently in place, according to the release.
“Higher rebates don’t typically result in lower out-of-pocket costs for patients, especially for Medicare patients,” said Murdo Gordon, executive vice president of Global Commercial Operations at Amgen. “We are confident today's action will address this challenge.”
Evolocumab’s original list price of $14,000 is expected to be phased out by late 2020.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.